FibroGen, Inc. Reports Interim Results of a Phase 1 / 2 Trial of FG-3019 in Locally Advanced or Metastatic Pancreatic Cancer

SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc. today announced interim results of a phase 1 / 2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor (CTGF), in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer. FG-3019 has been well-tolerated, no dose-limiting toxicities have been observed, and dose escalation continues. The interim results were reported at 2011 Gastrointestinal Cancers Symposium, co-sponsored by The American Society of Clinical Oncology (ASCO), in San Francisco, CA (Abstract #269).